First Horizon Advisors, Inc. Exagen Inc. Transaction History

First Horizon Advisors, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$2.69 - $8.68 $228 - $737	85 Added 6.57%	1,378 $3,000
Q2 2022 Aug 02, 2022	BUY	$4.18 - $7.74 $3,335 - $6,176	798 Added 161.21%	1,293 $7,000
Q1 2022 May 10, 2022	SELL	$7.12 - $11.06 $5,119 - $7,952	-719 Reduced 59.23%	495 $4,000
Q3 2021 Nov 09, 2021	BUY	$10.25 - $15.21 $12,443 - $18,464	1,214 New	1,214 $16,000

6.41M

4.5K

400

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $89.8M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.